** Shares of cancer drug developer Effector Therapeutics
EFTR.O up ~7% at $7.83 premarket
** Co publishes pre-clinical data highlighting the
anti-tumor potential of its drug candidate, zotatifin
urn:newsml:reuters.com:*:nGNX2JXLGg
** Data shows zotatifin suppressed the expression of certain
proteins that are mutated and over-expressed in many cancers
** Research also shows combinations of zotatifin with other
cancerous protein inhibitors led to enhanced anti-tumor activity
- EFTR
** Up to Tuesday's close, stock had fallen 26.23% since its
debut on March 1
(Reporting by Oishee Majumdar in Bengaluru)
((oishee.majumdar@thomsonreuters.com;))